Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

Epigenetic regulators, such as EZH2, are frequently mutated in cancer, and loss-of-function EZH2 mutations are common in myeloid malignancies. We have examined the importance of cellular context for Ezh2 loss during the evolution of acute myeloid leukemia (AML), where we observed stage-specific and...

Descripción completa

Detalles Bibliográficos
Autores principales: Basheer, Faisal, Giotopoulos, George, Meduri, Eshwar, Yun, Haiyang, Mazan, Milena, Sasca, Daniel, Gallipoli, Paolo, Marando, Ludovica, Gozdecka, Malgorzata, Asby, Ryan, Sheppard, Olivia, Dudek, Monika, Bullinger, Lars, Döhner, Hartmut, Dillon, Richard, Freeman, Sylvie, Ottmann, Oliver, Burnett, Alan, Russell, Nigel, Papaemmanuil, Elli, Hills, Robert, Campbell, Peter, Vassiliou, George S., Huntly, Brian J.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446874/
https://www.ncbi.nlm.nih.gov/pubmed/30890554
http://dx.doi.org/10.1084/jem.20181276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446874/
https://www.ncbi.nlm.nih.gov/pubmed/30890554
http://dx.doi.org/10.1084/jem.20181276

Ejemplares similares